DOCS - Doximity, Inc. Latest News | Finranks

11.08.2026

Atlassian and Doximity Just Surged 30% After Earnings: 3 Software Stocks with the Same Setup

Recent commentary in the DevSecOps sector has been positive, which could help fuel GitLab's revenue. UiPath is a highly shorted stock that could defy expectations.

08.08.2026

Why Doximity Stock Skyrocketed on Friday

Doximity's AI assistant is earning favorable reviews from independent researchers. Customer usage of Doximity's AI services is soaring.

08.08.2026

Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade)

Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS's evolving business model and earnings strength. DOCS is transforming physician searches into a new commercial marketplace, leveraging AI Search to monetize real-time physician intent.

08.08.2026

Doximity Q1 Earnings Call Highlights

Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.

07.08.2026

DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up

Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.

07.08.2026

Sell Doximity Into The Major Rally Following Its Q1 Results

Doximity, Inc. surged over 180% pre-market after its Q1 FY27 print, despite only marginally beating on revenue and missing on earnings. Fiscal Q3 revenue guidance of $170.5M at the midpoint is about 13% above consensus, signaling a potential inflection in growth expectations. Recent growth had slowed to just 5% in Q4, so the new guidance represents a notable acceleration relative to prior quarters.

07.08.2026

Doximity stock is reversing post-earnings rally: why that shouldn't surprise you

Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance. Still, a closer look under the hood suggests these explosive gains are built on a fragile foundation, and the company might just end up paring them back in the days ahead.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
DOCS	Wells Fargo	Underweight	undefined >> $18	August 10th 2026

Press releases

06.08.2026

Doximity Announces Fiscal 2027 First Quarter Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 first quarter ended June 30, 2026. “We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement,” said Jeff Tangney, co-founder and CEO of Doximity. "In Q1 we had accelerated revenue growth along with workflow active.

Doximity, Inc. (DOCS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Doximity, Inc. (DOCS)